RIBOMIC : Announces Publication of a Research Paper on an Aptamer Creation Platform Technology for Membrane Receptor GPCR

News Release

RIBOMIC Announces Publication of a Research Paper on an Aptamer Creation Platform Technology for Membrane Receptor GPCR

TOKYO, April 26, 2021 - RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TYO:4591), today announced that research results on a versatile method of creating aptamers for membrane receptor GPCR, a challenging drug discovery target, have been published in Proceedings of the National Academy of Sciences of the United States of America. The study was conducted in collaboration with the Project Division of RNA Medical Science, Institute of Medical Sciences, the University of Tokyo (Associate Professor, Takahashi) under the support by AMED (Japan Agency for Medical Research and Development).

Journal Name	Proceedings of the National Academy of Sciences of the United
	States of America (PNAS)
Article Title	Nucleic acid ligands act as a PAM and agonist depending on the
	intrinsic ligand binding state of P2RY2
Article URL	https://www.pnas.org/cgi/doi/10.1073/pnas.2019497118

In this study, we report a method for the discovery of an aptamer against GPCRs by an advanced RNA aptamer screening technology that employs a virus-like particle (VLP), exposing the GPCR of interest.

ABOUT GPCR

G protein-coupled receptors (GPCRs) play diverse roles in physiological processes, and hence the ligands to modulate GPCRs have served as important molecules in biological and pharmacological approaches. However, because of its complex composition buried in the plasma membrane, which makes it difficult to isolate with maintained activity, the exploration of novel ligands for GPCR still remains an arduous challenge.

ABOUT RIBOMIC

RIBOMIC is a bio-venture company centered on drug discovery. The company is engaged in the field of aptamer therapeutics, which is one type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company's core drug discovery platform, can be used for the discovery of many types of aptamer drugs. RIBOMIC is dedicated to the discovery and development of drugs that target the broad field of unmet medical needs, which encompasses eye disorders, pain and many other conditions.

See RIBOMIC website for more information. https://www.ribomic.com/eng/

Forward-Looking Statements

This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company's current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties.

Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

"RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

Contacts for inquiries or additional information: RIBOMIC Inc.

Finance and Accounting [e-mail]